Antimicrobial Resistance Profile of Helicobacter pylori in Shenzhen, China: A Retrospective Study From 2021 to 2024 [0.03%]
中国深圳市2021至2024年幽门螺杆菌耐药性回顾性研究
Fan Wu,Ye Chen,Chenghai Yang
Fan Wu
Background: The escalating antibiotic resistance of Helicobacter pylori (H. pylori) poses a significant threat to global public health. Continuous local surveillance is crucial due to substantial geographical and temporal...
High Potency Proton Pump Inhibitor Versus Vonoprazan in Helicobacter pylori Triple Therapy [0.03%]
高活性质子泵抑制剂与vonoprazan三联疗法根除幽门螺杆菌的疗效比较研究
Mimi C Tan,Robert L Atmar,David Y Graham
Mimi C Tan
Background: The price of vonoprazan in the United States, as with many newly introduced drugs, is currently high. Here, we examined the cost-effectiveness of vonoprazan clarithromycin triple therapy for treatment of Helic...
Evidence-Based Guidelines for the Diagnosis and Treatment of Helicobacter pylori Infection in Korea: 2025 Revised Edition [0.03%]
韩国幽门螺杆菌感染诊断和治疗循证指南（2025年修订版）
Chang Seok Bang,Seung Joo Kang,Hyunchul Lim et al.
Chang Seok Bang et al.
Background/aims: Since the 2020 Korean guidelines for Helicobacter pylori treatment, clarithromycin resistance rates have risen from 17.8% to 33.3%, dual-priming oligonucleotide-based polymerase chain reaction (DPO-PCR)-b...
Active Helicobacter pylori Infection and Survival Outcomes in De Novo Metastatic Colorectal Cancer: A Retrospective Cohort Study [0.03%]
活动性幽门螺杆菌感染与初诊转移性结直肠癌患者生存结局：回顾性队列研究
Sait Kitapli,Ali Alkan,Ozgur Tanriverdi
Sait Kitapli
Background: The prognostic significance of Helicobacter pylori (H. pylori) infection in metastatic colorectal cancer (mCRC) remains uncertain. Most prior studies have focused on colorectal neoplasia risk and have relied o...
Current Status of Diagnosis, Treatment, and Prevention of Helicobacter pylori Infection in China: A 2024-2025 National Multicenter Cross-Sectional Study [0.03%]
中国幽门螺杆菌感染诊断、治疗和预防现状：2024-2025年全国多中心横断面研究
Zhihao Yin,Zhiqiang Song,Xinlu Ren et al.
Zhihao Yin et al.
Background: This study aimed to investigate the current knowledge, attitudes, and practices of Chinese physicians regarding the management of Helicobacter pylori infection through a large-scale national survey. ...
Multicenter Study
Helicobacter. 2026 Jul-Aug;31(4):e70151. DOI:10.1111/hel.70151 2026
Worldwide Phylogenetic and Clinical Risk Association of the Helicobacter pylori Outer Membrane Gene hopQ [0.03%]
Helicobacter pylori外膜基因hopQ的全球系统发育和临床风险关联性分析
Edson I Rubio-Hernández,Ezequiel M Fuentes-Pananá,Kaisa Thorell et al.
Edson I Rubio-Hernández et al.
Background: Helicobacter pylori (Hp) infection is the primary risk factor for gastric cancer, yet the consequences of the infection vary by bacterial and host factors. The outer membrane protein HopQ plays a key role in H...
Global Diversity of Helicobacter pylori Prophages Reveals Genetic Drivers of Virulence and Associations With Gastric Cancer [0.03%]
全球Helicobacter pylori噬菌体基因组多样性揭示毒力遗传驱动因素和胃癌关联性
Zhenkai Li,Ying Li,Shixuan Huang et al.
Zhenkai Li et al.
Background: Helicobacter pylori is a globally prevalent gastric pathogen, and chronic infection accounts for most gastric cancer (GC) cases worldwide. Major oncogenic determinants, including CagA, VacA, and the type IV se...
How to Improve Patient Adherence During Helicobacter pylori Diagnosis and Treatment [0.03%]
提高幽门螺杆菌诊断和治疗中患者的依从性的方法
Song-Ze Ding,Shailja C Shah,Aaron P Thrift et al.
Song-Ze Ding et al.
Efficacy and Safety of Tegoprazan-Based Dual, Triple, and Quadruple Therapies in First-Line Helicobacter pylori Eradication: A Prospective Randomized Controlled Trial [0.03%]
替加酶唑为基础的二联、三联和四联疗法根除首次治疗幽门螺杆菌感染的有效性和安全性：一项前瞻性随机对照试验
Yu-Cheng Zhu,Keng Li,Anjiang Sun et al.
Yu-Cheng Zhu et al.
Background: Resistance to antibiotics has resulted in the effectiveness of conventional eradication therapies for Helicobacter pylori being reduced, creating a need for regimens that are effective, safe, and simple. In th...
Randomized Controlled Trial
Helicobacter. 2026 May-Jun;31(3):e70147. DOI:10.1111/hel.70147 2026
Efficacy and Safety of Fexuprazan-Based Modified High-Dose Dual Therapy for Helicobacter pylori Eradication: A Randomized Clinical Trial [0.03%]
菲波普拉唑为基础的大剂量双联疗法根除幽门螺杆菌的疗效和安全性：一项随机临床试验
Ji Yong Ahn,Ki-Nam Shim,Jung-Ho Park et al.
Ji Yong Ahn et al.
Background/aims: The eradication efficacy of proton pump inhibitor (PPI)-based standard triple therapy (STT) for Helicobacter pylori infection has declined in Korea, largely because of increasing clarithromycin resistance...